John Renger - Aug 5, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Scientific Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Aug 5, 2022
Transactions value $
-$922,500
Form type
4
Date filed
8/9/2022, 09:23 PM
Previous filing
Jul 22, 2022
Next filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $70K +20K +739.64% $3.50* 22.7K Aug 5, 2022 Direct F1
transaction CERE Common Stock Sale -$650K -20K -88.09% $32.50 2.7K Aug 5, 2022 Direct F1
transaction CERE Common Stock Options Exercise $35K +10K +369.82% $3.50* 12.7K Aug 8, 2022 Direct F1
transaction CERE Common Stock Sale -$378K -10K -78.72% $37.75 2.7K Aug 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -20K -14.31% $0.00 120K Aug 5, 2022 Common Stock 20K $3.50 Direct F1, F2
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10K -8.35% $0.00 110K Aug 8, 2022 Common Stock 10K $3.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.